Changes in Calcitonin Gene RNA Processing During Growth of a Human Medullary Thyroid Carcinoma Cell Line1

Total Page:16

File Type:pdf, Size:1020Kb

Changes in Calcitonin Gene RNA Processing During Growth of a Human Medullary Thyroid Carcinoma Cell Line1 (CANCER Ri:Si:\ROI 49. 6949-6952. December 15. 1989] Changes in Calcitonin Gene RNA Processing during Growth of a Human Medullary Thyroid Carcinoma Cell Line1 Barry D. Nelkin,2 Kurt Y. Chen, AndréedeBustros, Bernard A. Roos, and Stephen B. Baylin The Oncology Center, Johns Hopkins I'niversity School of Medii -inc. Baltimore, Maryland 21205 /B. I). ,V.. K. Y. C., A. de B., S. H. H./; the (ieriatric Research. Education, ami Clinical Center (dRECC). I 'eterans Administration Medical Center, Tacoma. H'ashington 98493 /B. A. R./: and the I 'nirersily of Hushinnton, Seattle, Washington VXIV? [R. A. R.I ABSTRACT sive product (2). To date, the factors influencing the posttran scriptional choice of CT or CGRP mRNA remain unknown. The ratios of calcitonin (CT) to calcitonin gene-related peptide (CGRP) We have studied CT gene regulation in the TT cell line, mRNA, both generated by alternative RNA processing from the same which was derived from a rapidly growing human MTC (7) and primary RNA transcript, arc shown by Northern blotting of cytoplasmic RNA to vary as a function of growth in a human medullary thyroid produces high levels of both CT and CGRP. We have previously carcinoma cell line ('IT). I'pon initial seeding, CT mRNA levels are shown that, in this cell line, levels of the CT peptide are relatively high, and CGRP mRNA levels are relatively low. During the modulated dynamically during various stages of growth in early logarithmic growth phase, CGRP mRNA levels rise severalfold, culture, being lowest during times of rapid cell proliferation while CT mRNA levels change only slightly. As the cells approach and highest in cells at saturation density (8). In vivo, it has also confluence, both CT and CGRP mRNA levels rise. Subsequently, CGRP been found that CT is decreased in MTC only from patients mRNA levels fall substantially in postconfluent cells, while CT mRNA with rapidly growing, aggressive tumors. In order to determine levels remain high. By actinomycin I) blocking of nascent transcription, the dynamics of CT gene expression which may regulate this we have shown that these growth-related, reversible changes in the ratio modulation of CT production, we have examined, using several of CT to CGRP mRNA arc not due to changes in mRNA stability. Our data rather suggest that 'IT cells reversibly alter alternative RNA- cDNA probes (4), CT gene-derived RNA production during processing patterns dependent upon growth conditions in vitro, such that growth of MTC cells in culture. We now find that the basis for (I mRNA is lowest and CGRP mRNA is highest during rapid growth. this difference is largely at the RNA level and that CT gene The mechanisms underlying this RNA-processing alteration may play a expression bears a complex and dynamically regulated relation role in certain patients with aggressive forms of medullary thyroid ship to cell growth. This regulation includes reversible changes carcinoma, in whom a decrease or loss of CT levels heralds a poor in posttranscriptional processing which lead to changing ratios prognosis. of the relative levels of CGRP to CT mRNAs and in part involves a reversible switch in choice of RNA processing to CT INTRODUCTION or CGRP mRNA. MTC1 is an important experimental system, biologically and clinically, for studies of both peptide hormone gene expression MATERIALS AND METHODS and tumor differentiation and progression. Both the tumor and Cell Culture. TT cells were seeded on day 0 at 1 x IO6cells/25 cm2 its normal counterpart, the thyroid C-cell, express the calcitonin flask, taking care to achieve a single cell suspension, and grown in gene. RPMI 1640 with 16% heat-inactivated fetal bovine serum (Gibco), 2 In both rat and human, the CT gene is composed of six exons HIMglutamine, 100 units/ml penicillin, and 100 i<u ml streptomycin, (Fig. 1) (1-3). By alternative processing of a single primary as described previously (8). The medium was changed on day 6. Under RNA transcript, two separate mature mRNAs derive from this these conditions, the cells have a doubling time of 83 h. In the experi one gene. The mRNA for CT itself contains sequences from ment shown in Fig. 4, TT cells were seeded as above, but serum was exons 1-4, and the mRNA for CGRP contains sequences from reduced to 10% and the medium was changed every 2 days. exons 1-3 and 5-6; during processing of the initial RNA RNA Hybridization and Electrophorcsis. Cells were harvested after various times, and cytoplasmic RNA was extracted using the vanadyl transcript to generate CGRP mRNA, exon 4 is treated as part ribonucleoside complex method (9). Two ug of total cytoplasmic RNA of an intron and is removed. The choice of mRNA produced, from each time point were denatured, electrophorcsed on 1.5% form made at the posttranscriptional RNA-processing level, varies aldehyde gels, and blotted to nitrocellulose (10). Blots were probed with specifically among normal tissues. Thus, normal thyroid C-cells human CT (exon 4)-specific cDNA clone pTT1062. a CGRP-specific predominantly produce CT mRNA, while many cells of the (exons 5 and 6) Äanll restriction fragment of cDNA clone pTT42, or a "common region" (sequences present in both CT and CGRP mRNAs; central nervous system and some other neuroendocrine cells predominantly produce CGRP (3). In the rat, transplantable see Fig. 1(-specific (exons 2 + 3) specific fragment of pTT42 (4). A medullary thyroid carcinoma can differ from normal C-cells in Pvu\\-Pst\ CGRP-1 (11(-specific fragment of pTT42, containing exon 6 and 17 base pairs of exon 5, gave the same results as the ßanll the mode of posttranscriptional processing of the CT gene, and fragment. Autoradiographic density was measured on a Clifford Den- an increase in CGRP mRNA can correlate with a decrease in sicomp densitometer. Loading of RNA was normali/ed by rehybridizing CT mRNA; in some cases, CGRP mRNA is almost the exclu- filters with a /i-actin cDNA probe (pAl, provided by D. Cleveland, Receivcd 2/12/88: revised 6/5/89; accepted 8/24/89. Johns Hopkins University School of Medicine). The actual fraction of The costs of publication of this article were defrayed in part by the payment the total CT gene derived mRNA expressed as CT or CGRP mRNA of page charges. This article must therefore be hereby marked advertisement in was estimated by |-x-32P|ATP end labeling or reverse transcription of accordance with 18 tJ.S.C. Section 1734 solely to indicate this fact. 1This work was supported in part by grants from the American Cancer Society RNA extracted from TT cells at various time points and hybridization to CT- or CGRP-specific plasmid DNA sequences immobili/cd on (PDT-207 and NP-533): the American Cancer Society. Maryland Division. Inc.: the NIH (AM .16116); and the Veterans Administration: and by gifts from the nitrocellulose (12) (data not shown). W. W. Smith Foundation and the Hodson Trust. CT and CGRP mRNA Half-Life Measurements. TT cells were seeded 2To whom requests for reprints should be addressed, at the Oncology Center as described above. On days 3, 7, or 11, actinomycin D (8 /¿g/ml)was Research Laboratories. Johns Hopkins University School of Medicine. 424 N. added to block transcription, and cells were harvested after various Bond Street. Baltimore, MD 21231. 1The abbreviations used are: MTC. medullary thyroid carcinoma; CT. calci further incubation times. This method was chosen instead of pulse- tonin: CGRP. calcitonin gene-related peptide; cDNA, complementary DNA. chase techniques (13) since the high concentration of pyrimidines 6949 Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 1989 American Association for Cancer Research. CT RNA PROCESSING CHANGES IN CELL GROWTH CGRP CGRP Common_nLJiCommon2n~Lr~ CT Coding Codmq Untronsloted A Day iRNACTr—LProcessing 79 CT VGRP mRNA Common Region Specil'cCD Probe )CGRP Specific Probe ]CT Spec.lie CGRP Probe Fig. I. Overview of human calcitonin gene structure and expression. Alter native RNA processing produces two mRNAs. one encoding CT [1.0 kilobase (AA)|and one encoding CGRP [1.1 kilobases). Specific common region (exons 2 and 3). CT (exon 4), and CGRP (exons 5 and 6) hybridization probes shown were derived from cloned cDNAs (4). Data from Refs. 1 and 4-6. required for pulse-chase are toxic to TT cells. RNA was extracted as described above, and 2 ¿tgwereapplied to nitrocellulose using a slot blot manifold (Schleicher and Schuell, Keene, NH). Slot blots were hybridized with the CT- and CGRP-specific probes described above. RESULTS We have examined, by Northern blotting using CT- and CGRP-specific mRNA probes, the dynamic variation of the relative levels of these mRNAs in TT cells during growth. Fig. 2, A and B, shows that, during TT cell growth, CT-specific mRNA levels generally paralleled those of total CT gene- derived mRNA (Fig. 2Ä);these relative mRNA levels remained constant or decreased for several days after cell seeding and then gradually increased as the cells progressed toward conflu ence (after day 6). These changes in CT mRNA levels were consistent with our previous observation that CT peptide levels fall during the initial growth phase of the TT cells and increase to initial levels at confluence (8). Thus, CT peptide production in these cells during growth appears to be largely regulated at the mRNA level. When the hybridization was repeated using a CGRP-specific probe (exons 5 and 6), a different pattern emerged. It became apparent that the relative levels of CGRP mRNA varied during growth, in a pattern unlike that of CT-specific or overall CT gene-derived mRNA. Thus, for the first 2-3 days after the cells Fig.
Recommended publications
  • NIH Public Access Author Manuscript Gene
    NIH Public Access Author Manuscript Gene. Author manuscript; available in PMC 2010 June 21. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Gene. 2007 July 15; 396(2): 373±390. doi:10.1016/j.gene.2007.04.021. Formation of the 3’ end of histone mRNA: Getting closer to the end Zbigniew Dominski* and William F. Marzluff Department of Biochemistry and Biophysics and Program in Molecular Biology and Biotechnology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA Abstract Nearly all eukaryotic mRNAs end with a poly (A) tail that is added to their 3’ end by the ubiquitous cleavage/polyadenylation machinery. The only known exception to this rule are metazoan replication dependent histone mRNAs, which end with a highly conserved stem-loop structure. This distinct 3’ end is generated by specialized 3’end processing machinery that cleaves histone pre-mRNAs 4–5 nucleotides downstream of the stem-loop and consists of the U7 small nuclear RNP (snRNP) and number of protein factors. Recently, the U7 snRNP has been shown to contain a unique Sm core that differs from that of the spliceosomal snRNPs, and an essential heat labile processing factor has been identified as symplekin. In addition, cross-linking studies have pinpointed CPSF-73 as the endonuclease, which catalyzes the cleavage reaction. Thus, many of the critical components of the 3’ end processing machinery are now identified. Strikingly, this machinery is not as unique as initially thought but contains a number of factors involved in cleavage/polyadenylation, suggesting that the two mechanisms have a common evolutionary origin.
    [Show full text]
  • The Role of Nuclear Bodies in Gene Expression and Disease
    Biology 2013, 2, 976-1033; doi:10.3390/biology2030976 OPEN ACCESS biology ISSN 2079-7737 www.mdpi.com/journal/biology Review The Role of Nuclear Bodies in Gene Expression and Disease Marie Morimoto and Cornelius F. Boerkoel * Department of Medical Genetics, Child & Family Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-604-875-2157; Fax: +1-604-875-2376. Received: 15 May 2013; in revised form: 13 June 2013 / Accepted: 20 June 2013 / Published: 9 July 2013 Abstract: This review summarizes the current understanding of the role of nuclear bodies in regulating gene expression. The compartmentalization of cellular processes, such as ribosome biogenesis, RNA processing, cellular response to stress, transcription, modification and assembly of spliceosomal snRNPs, histone gene synthesis and nuclear RNA retention, has significant implications for gene regulation. These functional nuclear domains include the nucleolus, nuclear speckle, nuclear stress body, transcription factory, Cajal body, Gemini of Cajal body, histone locus body and paraspeckle. We herein review the roles of nuclear bodies in regulating gene expression and their relation to human health and disease. Keywords: nuclear bodies; transcription; gene expression; genome organization 1. Introduction Gene expression is a multistep process that is vital for the development, adaptation and survival of all living organisms. Regulation of gene expression occurs at the level of transcription, RNA processing, RNA export, translation and protein degradation [1±3]. The nucleus has the ability to modulate gene expression at each of these levels. How the nucleus executes this regulation is gradually being dissected.
    [Show full text]
  • Purified U7 Snrnps Lack the Sm Proteins D1 and D2 but Contain
    The EMBO Journal Vol. 20 No. 19 pp. 5470±5479, 2001 Puri®ed U7 snRNPs lack the Sm proteins D1 and D2 but contain Lsm10, a new 14 kDa Sm D1-like protein Ramesh S.Pillai1, Cindy L.Will2, The U11 and U12 snRNPs contain the common Sm Reinhard LuÈ hrmann2, Daniel SchuÈ mperli1,3 proteins, interacting with canonical Sm binding sites, and Berndt MuÈ ller1,4 certain U2 snRNP-speci®c proteins also present in the U12 snRNP, and new kinds of U11 and U12 snRNP-speci®c 1 Institute of Cell Biology, University of Bern, Baltzerstrasse 4, 3012 proteins that may be functional equivalents of U1- and U2- Bern, Switzerland, 2Max Planck Institute of Biophysical Chemistry, Am Fassberg 11, 37070 GoÈttingen, Germany and 4Department of speci®c proteins (Will et al., 1999). Molecular and Cell Biology, Institute of Medical Sciences, University Another minor snRNP, the U7 snRNP, is an essential of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK cofactor for 3¢-end processing of the replication-dependent 3Corresponding author histone pre-mRNAs in metazoans (reviewed in MuÈller and e-mail: [email protected] SchuÈmperli, 1997; Dominski and Marzluff, 1999). These histone transcripts lack introns and a poly(A) tail in the U7 snRNPs were isolated from HeLa cells by biochem- mature message. The endonucleolytic cleavage generating ical fractionation, followed by af®nity puri®cation the mRNA 3¢-end is distinct from the cleavage-poly- with a biotinylated oligonucleotide complementary to adenylation reaction that processes all other mRNAs. The U7 snRNA. Puri®ed U7 snRNPs lack the Sm proteins U7 snRNA is 58±63 nucleotides (nt) long, depending on D1 and D2, but contain additional polypeptides of 14, the species.
    [Show full text]
  • Coding RNA Genes
    Review A guide to naming human non-coding RNA genes Ruth L Seal1,2,* , Ling-Ling Chen3, Sam Griffiths-Jones4, Todd M Lowe5, Michael B Mathews6, Dawn O’Reilly7, Andrew J Pierce8, Peter F Stadler9,10,11,12,13, Igor Ulitsky14 , Sandra L Wolin15 & Elspeth A Bruford1,2 Abstract working on non-coding RNA (ncRNA) nomenclature in the mid- 1980s with the approval of initial gene symbols for mitochondrial Research on non-coding RNA (ncRNA) is a rapidly expanding field. transfer RNA (tRNA) genes. Since then, we have worked closely Providing an official gene symbol and name to ncRNA genes brings with experts in the ncRNA field to develop symbols for many dif- order to otherwise potential chaos as it allows unambiguous ferent kinds of ncRNA genes. communication about each gene. The HUGO Gene Nomenclature The number of genes that the HGNC has named per ncRNA class Committee (HGNC, www.genenames.org) is the only group with is shown in Fig 1, and ranges in number from over 4,500 long the authority to approve symbols for human genes. The HGNC ncRNA (lncRNA) genes and over 1,900 microRNA genes, to just four works with specialist advisors for different classes of ncRNA to genes in the vault and Y RNA classes. Every gene symbol has a ensure that ncRNA nomenclature is accurate and informative, Symbol Report on our website, www.genenames.org, which where possible. Here, we review each major class of ncRNA that is displays the gene symbol, gene name, chromosomal location and currently annotated in the human genome and describe how each also includes links to key resources such as Ensembl (Zerbino et al, class is assigned a standardised nomenclature.
    [Show full text]
  • Exploring Mammalian Genome Within Phase-Separated Nuclear Bodies: Experimental Methods and Implications for Gene Expression
    G C A T T A C G G C A T genes Review Exploring Mammalian Genome within Phase-Separated Nuclear Bodies: Experimental Methods and Implications for Gene Expression Annick Lesne 1,2,*, Marie-Odile Baudement 1,3 , Cosette Rebouissou 1 and Thierry Forné 1,* 1 IGMM, Univ. Montpellier, CNRS, F-34293 Montpellier, France; [email protected] (M.-O.B.); [email protected] (C.R.) 2 Sorbonne Université, CNRS, Laboratoire de Physique Théorique de la Matière Condensée, LPTMC, F-75252 Paris, France 3 Centre for Integrative Genetics (CIGENE), Faculty of Biosciences, Norwegian University of Life Sciences, 1430 Ås, Norway * Correspondence: [email protected] (A.L.); [email protected] (T.F.); Tel.: +33-434-359-682 (T.F.) Received: 6 November 2019; Accepted: 13 December 2019; Published: 17 December 2019 Abstract: The importance of genome organization at the supranucleosomal scale in the control of gene expression is increasingly recognized today. In mammals, Topologically Associating Domains (TADs) and the active/inactive chromosomal compartments are two of the main nuclear structures that contribute to this organization level. However, recent works reviewed here indicate that, at specific loci, chromatin interactions with nuclear bodies could also be crucial to regulate genome functions, in particular transcription. They moreover suggest that these nuclear bodies are membrane-less organelles dynamically self-assembled and disassembled through mechanisms of phase separation. We have recently developed a novel genome-wide experimental method, High-salt Recovered Sequences sequencing (HRS-seq), which allows the identification of chromatin regions associated with large ribonucleoprotein (RNP) complexes and nuclear bodies.
    [Show full text]
  • A Region of Slbp Distinct from the Histone Mrna Binding and Processing Domains Is Essential for Deposition of Histone Mrna in the Oocyte
    A REGION OF SLBP DISTINCT FROM THE HISTONE MRNA BINDING AND PROCESSING DOMAINS IS ESSENTIAL FOR DEPOSITION OF HISTONE MRNA IN THE OOCYTE Jennifer M. Potter-Birriel A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in particial fulfillment of the requirements for the degree of Doctor of Philosophy in the Curriculum of Genetics and Molecular Biology. Chapel Hill 2020 Approved by: William F. Marzluff Robert J. Duronio Jill Dowen Zbig Dominski Cyrus Vaziri © 2020 Jennifer M. Potter-Birriel ALL RIGHTS RESERVED ii ABSTRACT Jennifer M. Potter-Birriel: A region of Drosophila SLBP distinct from the histone pre-mRNA binding and processing domains is essential for deposition of histone mRNA in the oocyte (Under the direction of Bill Marzluff) Metazoan histone mRNAs are the only eukaryotic mRNAs that are not polyadenylated. Instead they end in a 3’end Stemloop (SL). Processing of the histones pre-mRNAs is accomplished by an endonucleolytic cleavage after the SL. The stem loop binding protein (SLBP) binds to the SL, and SLBP is a key factor in all steps of the life cycle of histone mRNAs. We are studying the role of SLBP in Drosophila melanogaster in vivo. In Drosophila each histone gene contains a cryptic polyA site after the histone processing site, and when histone pre- mRNA processing is defective histone mRNAs are polyadenylated. Using FLY-CRISPRCas9 we obtained a 11 deletion (SLBP∆11) null mutant and a 30 nucleotide deletion (SLBP∆30) in the N-terminal domain (NTD) of SLBP. The 30nt deletion removed 10aa from the N-terminal domain of SLBP in a region of unknown function distinct from the processing domain.
    [Show full text]
  • New Roles for the RNA Processing Factors Cfim68 and SRPK2 Highlight Unexpected Links in the Control of Mammalian Gene Expression
    PhD Program in Translational and Molecular Medicine DIMET XXII Cycle, Academic Year 2008-2009 University of Milano-Bicocca School of Medicine and Faculty of Science New roles for the RNA processing factors CFIm68 and SRPK2 highlight unexpected links in the control of mammalian gene expression Silvia Vivarelli – No. 708258 1 2 A mio padre, Agostino 3 4 TABLE OF CONTENTS Chapter 1............................................................................................. 8 GENERAL INTRODUCTION ......................................................... 8 1. The Alternative Splicing .............................................................. 8 1.1 The Alternative Splicing Mechanism..................................... 8 1.2 The Splicing Reaction ............................................................ 9 1.3 Alternative Splicing Regulation ........................................... 13 1.4 The SR Family of Proteins ................................................... 21 1.4.1 SR Proteins: an overview .................................................. 21 1.4.2 SR Proteins: a Vertical Integration of Gene Expression ... 25 1.4.3 SR Protein Kinases............................................................ 26 1.5 Signal Transduction Pathways: from Extracellular Stimuli to Alternative Splicing.................................................................... 29 1.6 Stressful Splicing: the Effects of Paraquat ........................... 30 2. The 3’ End Formation and Export.............................................. 31 2.1 Molecular
    [Show full text]
  • Ep 2811298 A1
    (19) TZZ __ _T (11) EP 2 811 298 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.12.2014 Bulletin 2014/50 G01N 33/53 (2006.01) G01N 33/542 (2006.01) (21) Application number: 13002949.9 (22) Date of filing: 07.06.2013 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Hall, Jonathan GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 4143 Dornach (CH) PL PT RO RS SE SI SK SM TR • Pradere, Ugo Designated Extension States: 8046 Zürich (CH) BA ME •Roos,Martina 8050 Zürich (CH) (71) Applicant: ETH Zurich 8092 Zurich (CH) (54) FRET-Method for identifying a biomolecule-modulating compound (57) The present invention relates to a method for the excitation energy spectrum of the fluorophore accep- identifying a compound modulating an interaction be- tor or the energy spectrum absorbed by the dark quench- tween two biomolecules or two domains of one biomol- er overlap at least partially. Preferably, the first and sec- ecule, the first biomolecule or first domain comprising at ond biomolecules are selected from the group consisting least one fluorophore donor and the second biomolecule of polypeptides, sugars, polynucleotides, polyamines or second domain comprising at least one fluorophore and lipids, and more preferably the first biomolecule is acceptor or a dark quencher, wherein the fluorophore selected from the group consisting of polypeptides inter- donor and fluorophore acceptor or the fluorophore donor acting with polynucleotides and the second biomolecule and dark quencher are spectrally paired such that the is selected from the group consisting of polynucleotides, energy spectrum emitted by.the fluorophore donor and preferably microRNAs (miRNA).
    [Show full text]
  • Rabbit Anti-LSM10 Antibody-SL18434R
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-LSM10 antibody SL18434R Product Name: LSM10 Chinese Name: LSM10相关蛋白抗体 LSM 10; LSM10 U7 small nuclear RNA associated; MGC15749; MST074; Alias: LSM10_HUMAN; MSTP074; U7 snRNA associated Sm like protein LSm10; U7 snRNP specific Sm like protein LSM10. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Cow,Horse,Rabbit, ELISA=1:500-1000IHC-P=1:400-800IHC-F=1:400-800ICC=1:100-500IF=1:100- 500(Paraffin sections need antigen repair) Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 14kDa Cellular localization: The nucleus Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human LSM10:1-80/123 Lsotype: IgGwww.sunlongbiotech.com Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. PubMed: PubMed LSM10 is a 14 kDa polypeptide that is a member of the Sm/Lsm protein family. Like U7 snRNA, LSM10 is enriched in Cajal or coiled bodies (CBs) in the nucleus.
    [Show full text]
  • A Cell Biological Determination of Integrator Subunit Localization
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 8-2011 A Cell Biological Determination of Integrator Subunit Localization Sarah B. May Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Biology Commons, and the Cell Biology Commons Recommended Citation May, Sarah B., "A Cell Biological Determination of Integrator Subunit Localization" (2011). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 173. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/173 This Thesis (MS) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. A CELL BIOLOGICAL DETERMINATION OF INTEGRATOR SUBUNIT LOCALIZATION By: Sarah Beth May, B.S. APPROVED: Eric Wagner, Ph.D. (Supervisory Advisor) Michael Blackburn, Ph.D. Phillip Carpenter, Ph.D. Joel Neilson, Ph.D. Ambro van Hoof, Ph.D. APPROVED: Dean, The University of Texas Graduate School of Biomedical Sciences at Houston A CELL BIOLOGICAL DETERMINATION OF INTEGRATOR SUBUNIT LOCALIZATION A THESIS Presented to the Faculty of The University of Texas Health Science Center at Houston and The University of Texas M.D.
    [Show full text]
  • Studies with Recombinant U7 Snrnp Demonstrate That CPSF73 Is Both an Endonuclease and a 5’-3’ Exonuclease
    Downloaded from rnajournal.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Studies with recombinant U7 snRNP demonstrate that CPSF73 is both an endonuclease and a 5’-3’ exonuclease Xiao-cui Yang1, Yadong Sun2, Wei Shen Aik2#, William F. Marzluff1,3, Liang Tong2* and Zbigniew Dominski1,3* 1Integrative Program for Biological and Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA 2Department of Biological Sciences, Columbia University, New York, NY 10027, USA 3Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA XY and YS contributed equally to this work # Present address: Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR * Correspondence should be addressed to ZD ([email protected]) or LT ([email protected]) Running title: CPSF73 is an endonuclease and 5’-3’ exonuclease Keywords histone pre-mRNA, U7 snRNP, CPSF73, 3’ end processing, symplekin Downloaded from rnajournal.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press ABSTRACT Metazoan replication-dependent histone pre-mRNAs are cleaved at the 3’ end by U7 snRNP, an RNA-guided endonuclease that contains U7 snRNA, seven proteins of the Sm ring, FLASH and four polyadenylation factors: symplekin, CPSF73, CPSF100 and CstF64. A fully recombinant U7 snRNP was recently reconstituted from all 13 components for functional and structural studies and shown to accurately cleave histone pre-mRNAs. Here, we analyzed the activity of recombinant U7 snRNP in more detail. We demonstrate that in addition to cleaving histone pre- mRNAs endonucleolytically, reconstituted U7 snRNP acts as a 5’-3’ exonuclease that degrades the downstream product generated from histone pre-mRNAs as a result of the endonucleolytic cleavage.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,534.879 B2
    USOO7534879B2 (12) United States Patent (10) Patent No.: US 7,534.879 B2 Van Deutekom 45) Date of Patent: MaV 19,9 2009 (54) MODULATION OF EXON RECOGNITION IN WO 2004/083432 A1 9, 2004 PRE-MRNABY INTERFERING WITH THE OTHER PUBLICATIONS SECONDARY RNASTRUCTURE Aartsma-Rus et al., Targeted exon skipping as a potential gene cor rection therapy for Duchenne muscular dystrophy, Neuromuscular (75) Inventor: Judith C.T. van Deutekom, Dordrecht Disorders, 2002, S71-S77, vol. 12. (NL) Dickson et al., Screening for antisense modulation of dystrophin pre-mRNA splicing, Neuromuscul. Disord., 2002, S67-70, Suppl. 1. De Angelis et al., Chimeric SnRNA molecules carrying antisense (73) Assignee: Academisch Ziekenhuis Leiden, Leiden sequences against the splice junctions of exon 51 of the dystrophin (NL) pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in delta 48-50 DMD cells, PNAS, Jul. 9, 2002, pp. 9456 (*) Notice: Subject to any disclaimer, the term of this 9461, vol.99, No. 14. patent is extended or adjusted under 35 Dunckley et al., Modifications of splicing the dystrophin gene in U.S.C.M YW- 154(b) by 0 days S.olecular M Genetics,muscle t ,by pp. antigslides , Vol. , No. 1. Human Lu et al., Massive Idiosyncratic Exon Skipping Corrects the Non This patent is Subject to a terminal dis- sense Mutation in Dystrophic Mouse Muscle and Produces Func claimer. tional Revertant Fibers by Clonal Expansion. The Journal of Cell Biology, Mar. 6, 2000, pp.985-995, vol. 148, No. 5. (21) Appl. No.: 12/198,007 Mann et al., Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse, PNAS, Jan.
    [Show full text]